PRODUCT EVIDENCE JOURNAL · 09 / 10
The Therapy Cream’s two-week study: three wrinkle endpoints, one careful reading
A cream’s texture and a measured wrinkle outcome are different kinds of information. The study helps with the second - not every claim you might attach to the first.
NARINFLA JOURNAL · PRODUCT EVIDENCE SERIES

Official product photograph; not a study image.
On this page
What were the reported group averages?Does a two-week study prove the cream acts faster than 3F?Can the result be described as deep wrinkle repair?What about moisture and pairing with the ampoule?How can the evidence guide a realistic choice?- The 2024 ProBM cream report involved 20 women, average age 50.3 years, over two weeks.
- Mean changes were 18.1% for the under-eye measurement, 12.1% for nasolabial folds and 13.8% for the neck measurement.
- The report does not rank the cream against 3F or establish an additional effect from using the two together.
What were the reported group averages?
ProBM PM-24J19-WR026 · n=20 · two weeks
ProBM report PM-24J19-WR026 reports mean changes of 18.1% for under-eye wrinkles, 12.1% for nasolabial folds and 13.8% for neck wrinkles, rounded to one decimal place.
The 2024 study involved 20 women, with an average age of 50.3 years, and a two-week observation period. Those conditions belong beside the percentages because they identify the scope of the tested cream sample’s result.
Rounding makes the page easier to read without changing the kind of evidence. A one-decimal value is still a group mean; it should not become a guarantee that your own wrinkle measurement will change by that amount.
Does a two-week study prove the cream acts faster than 3F?
No. The cream and ampoule reports are separate studies rather than a direct comparison. Their different observation periods cannot establish which product is faster, stronger or better for every user.
The domestic 3F wrinkle report covers four weeks and a different tested product. Even if an endpoint has a similar name, the complete protocol, product sample and participant group would need to be considered before drawing comparative conclusions.
For the same reason, we do not place the cream’s two-week under-eye average beside the ampoule’s four-week average and declare a winner. That arrangement would look quantitative while answering a question neither study actually tested.
A two-week observation of the tested cream sample, 20 women, average age 50.3, three wrinkle measurements.
A separate four-week domestic ampoule observation, 20 women, average age 50. Not a head-to-head comparator.
Related evidence: Reading the 3F numbers: the average is not the best individual result. Official product ingredients and study information.
Can the result be described as deep wrinkle repair?
The report supports its defined wrinkle measurements, not an unrestricted claim of repairing deep skin structure. A measured change in appearance should not be translated into a promise of rebuilding tissue or replacing a procedure.
A product explanation may discuss the cream’s role in a skincare routine, but a familiar texture does not tell us which biological mechanism produced the reported changes. The finished formula was tested; the study does not isolate every ingredient’s contribution.
The same limit applies to clinical language. Naming ProBM and providing a report number improves traceability, but it does not supply unverified details about blinding, randomization or a placebo comparison. We do not add those features without the protocol.
What about moisture and pairing with the ampoule?
Those are separate questions. The three wrinkle outcomes do not automatically establish a quantified hydration result, long-term barrier recovery or extra benefit when the cream is layered over 3F.
A routine can include both products without becoming a clinically tested combination. To substantiate an added combined effect, we would need evidence addressing that combination and use conditions, rather than adding figures from individual-product reports.
We also avoid saying the cream locks in “density delivered by the ampoule” as a conclusion from this study. That phrase connects two products through a mechanism and a benefit the separate wrinkle report does not establish.
How can the evidence guide a realistic choice?
Keep the evidence in its own lane
A group result is not a guarantee for an individual.
A measurement applies to its stated sample, conditions and period.
A separate-product study is not a test of a combined routine.
Use it to understand what was observed for the tested cream, then consider the product directions and how a cream format fits your preferences. A matching study can be useful without answering every possible routine question.
For someone considering eye-area, nasolabial or neck wrinkle appearance, the three separate endpoints show the subjects of the research. They do not prescribe application to sensitive areas contrary to the label, or promise the same outcome on every face.
Personal comfort remains important. A study is not a reason to ignore stinging, apply more than directed or continue a routine that causes persistent redness. Ask for appropriate advice if skin is damaged, actively inflamed or recently treated.
The clearest description is the least inflated one: a 2024 ProBM report, a tested cream sample, 20 women and average changes measured over two weeks. That leaves room for a thoughtful decision instead of a competition between percentages.
Questions & answers
Why are the figures rounded to one decimal place?
For consistent clinical reporting and readability, the group means are displayed to one decimal place: 18.1%, 12.1% and 13.8%.
Does the study prove the cream improves the ampoule’s results?
No. The cream’s separate report does not establish an additional combined effect from layering it with 3F.
Does the report establish how long a change lasts after stopping?
The supplied report describes a two-week observation period. It does not establish permanent change or persistence after product use stops.
Sources and scope
- ProBM Intensive Therapy Cream study, 2024PM-24J19-WR026
Brand-held two-week report: 20 women, average age 50.3 years; under-eye, nasolabial and neck outcomes.
- ProBM domestic 3F wrinkle study, 2023PM-23A29-WR008
Brand-held human application report: 20 women, average age 50 years, four weeks; under-eye, nasolabial and neck outcomes. Full report is not publicly linked here.
- Technical document on cosmetic claims, Claims Sub-Working Group, 3 July 2017, Annexes I–II
Non-binding best-practice guidance on relevant evidence, product identity, study conditions and avoiding exaggerated interpretations; not a narinfla trial or European Commission legal ruling.
- narinfla official English product information
Official brand hub; consult the corrected version for product-specific information. Not a public archive of the full clinical reports.
Related reading
Read the official product facts →Information only. Follow the current package directions. Cosmetics do not replace diagnosis or treatment.